Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells

Life Sciences

Volumn 78, Issue 22, 2006, Pages 2550-2557

  Kuo, Yu Chun ^a   Kuo, Po Lin ^b   Hsu, Ya Ling ^a   Cho, Chien Yu ^a   Lin, Chun Ching ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

Apoptosis; Ellipticine; Fas Fas Ligand; Mitochondrial pathway; p53

Indexed keywords

CASPASE 3; CASPASE 9; DIMETHYL SULFOXIDE; DNA FRAGMENT; ELLIPTICINE; FAS ANTIGEN; FAS LIGAND; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; PROPIDIUM IODIDE; PROTEIN BCL 2; PROTEIN P53;

ANALYTIC METHOD; APOPTOSIS; ARTICLE; ASSAY; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; LIVER CELL CARCINOMA; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MOLECULAR BIOLOGY; PROTEIN EXPRESSION; PROTEIN FAMILY; RECEPTOR UPREGULATION; STAINING;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DNA; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ELLIPTICINES; FAS LIGAND PROTEIN; HUMANS; LIVER NEOPLASMS; MEMBRANE GLYCOPROTEINS; MEMBRANE POTENTIALS; MITOCHONDRIA, LIVER; MITOCHONDRIAL MEMBRANES; PLANT EXTRACTS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR NECROSIS FACTORS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

APOCYNACEAE; OCHROSIA ELLIPTICA;

EID: 33646056086     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2005.10.041     Document Type: Article

References (33)

1. Acton E.M., Narayanan V.L., Risbood P.A., Shoemaker R.H., Vistica D.T., and Boyd M.R. Anticancer specificity of some ellipticinium salts against human brain tumors in vitro. Journal of Medicinal Chemistry 37 (1994) 2185-2189
2. Anderson W.K., Gopalsamy A., and Reddy P.S. Design, synthesis, and study of 9-substituted ellipticine and 2-methylellipticinium analogues as potential CNS-selective antitumor agents. Journal of Medicinal Chemistry 37 (1994) 1955-1963
3. Allen R.T., Cluck M.W., and Agrawal D.K. Mechanisms controlling cellular suicide: role of Bcl-2 and caspases. Cellular and Molecular Life Sciences 54 (1998) 427-445
4. Bosch F.X., Ribes J., Diaz M., and Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 (2004) S5-S16
5. Castaneda F., and Kinne R.K. Apoptosis induced in HepG2 cells by short exposure to millimolar concentrations of ethanol involves the Fas-receptor pathway. Journal of Cancer Research and Clinical Oncology 127 (2001) 418-424
6. Cory S., and Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nature Reviews. Cancer 2 (2002) 647-656
7. Degli Esposti M. Mitochondria in apoptosis: past, present and future. Biochemical Society Transactions 32 (2004) 493-495
8. Galle P.R., Hofmann W.J., Walczak H., Schaller H., Otto G., Stremmel W., Krammer P.H., and Runkel L. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. The Journal of Experimental Medicine 182 (1995) 1223-1230
9. Garbett N.C., and Graves D.E. Extending nature's leads: the anticancer agent ellipticine. Current Medicinal Chemistry. Anti-Cancer Agents 4 (2004) 149-172
10. Giaccia A.J., and Kastan M.B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes & Development 12 (1998) 2973-2983
11. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
12. Hagg M., Berndtsson M., Mandic A., Zhou R., Shoshan M.C., and Linder S. Induction of endoplasmic reticulum stress by ellipticine plant alkaloids. Molecular Cancer Therapeutics 3 (2004) 489-497
13. Haupt S., Berger M., Goldberg Z., and Haupt Y. Apoptosis-the p53 network. Journal of Cell Science 116 (2003) 4077-4085
14. Hiramatsu N., Hayashi N., Katayama K., Mochizuki K., Kawanishi Y., Kasahara A., Fusamoto H., and Kamada T. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 19 (1994) 1354-1359
15. Ho J., and Benchimol S. Transcriptional repression mediated by the p53 tumour suppressor. Cell Death and Differentiation 10 (2003) 404-408
16. Jin S., and Levine A.J. The p53 functional circuit. Journal of Cell Science 114 (2001) 4139-4140
17. Kovacic P., Ames J.R., Lumme P., Elo H., Cox O., Jackson H., Rivera L.A., Ramirez L., and Ryan M.D. Charge transfer-oxy radical mechanism for anti-cancer agents. Anti-Cancer Drug Design 1 (1986) 197-214
18. Kuo P.L., Hsu Y.L., Kuo Y.C., Chang C.H., and Lin C.C. The anti-proliferative inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction. Anti-Cancer Drugs 16 (2005) 789-795
19. Kuo P.L., Hsu Y.L., Chang C.H., and Lin C.C. The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Letters 223 (2005) 293-301
20. Kuwana T., and Newmeyer D.D. Bcl-2-family proteins and the role of mitochondria in apoptosis. Current Opinion in Cell Biology 15 (2003) 691-699
21. Lesca P., Rafidinarivo E., Lecointe P., and Mansuy D. A class of strong inhibitors of microsomal monooxygenases: the ellipticines. Chemico-Biological Interactions 24 (1979) 189-197
22. Lohrum M.A., and Vousden K.H. Regulation and activation of p53 and its family members. Cell Death and Differentiation 6 (1999) 1162-1168
23. Mediavilla M.D., Cos S., and Sanchez-Barcelo E.J. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sciences 65 (1999) 415-420
24. Palissot V., Morjani H., Belloc F., Cotteret S., Dufer J., and Berchem G. From molecular characteristics to cellular events in apoptosis-resistant HL-60 cells. International Journal of Oncology 26 (2005) 825-834
25. Peng Y., Li C., Chen L., Sebti S., and Chen J. Rescue of mutant p53 transcription function by ellipticine. Oncogene 22 (2003) 4478-4487
26. Petros A.M., Olejniczak E.T., and Fesik S.W. Structural biology of the Bcl-2 family of proteins. Biochimica et Biophysica Acta 1644 (2004) 83-94
27. Rouesse J.G., Le Chevalier T., Caille P., Mondesir J.M., Sancho-Garnier H., May-Levin F., Spielmann M., De Jager R., and Amiel J.L. Phase II study of elliptinium in advanced breast cancer. Cancer Treatment Reports 69 (1985) 707-708
28. Schuler M., and Green D.R. Mechanisms of p53-dependent apoptosis. Biochemical Society Transactions 29 (2001) 684-688
29. Schwaller M.A., Allard B., Lescot E., and Moreau F. Protonophoric activity of ellipticine and isomers across the energy-transducing membrane of mitochondria. The Journal of Biological Chemistry 270 (1995) 22709-22713
30. Sheikh M.S., and Huang Y. Death receptors as targets of cancer therapeutics. Current Cancer Drug Targets 4 (2004) 97-104
31. Somasundaram S., Edmund N.A., Moore D.T., Small G.W., Shi Y.Y., and Orlowski R.Z. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Research 62 (2002) 3868-3875
32. Tassaneeyakul W., Birkett D.J., Veronese M.E., McManus M.E., Tukey R.H., Quattrochi L.C., Gelboin H.V., and Miners J.O. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics 265 (1993) 401-407
33. Timmer T., de Vries E.G., and de Jong S. Fas receptor-mediated apoptosis: a clinical application?. Journal of Pathology 196 (2002) 125-134